1. Clinical & Scientific Overview
Fenofibrate & Ezetimibe (TIP-MED-000043, Reference Code [3.43]) is classified under
Cardiovascular & Antithrombotic Medicines (Ch 03) as a PPAR-Alpha Agonist Fibrate & Intestinal NPC1L1 Cholesterol Absorption Inhibitor (Schedule H).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 03 [3.43], p. 42): Fenofibrate: Lipicard (USV), Fenolip (Cipla), Stanlip (Ranbaxy). Ezetimibe: Ezedoc (Lupin), Zetia, Ezentia (Sun); Statin FDCs: Atorva-EZ, Rosuvas-EZ, Rosuvas-F — Strengths & Dosage Forms: Fenofibrate Micronised/Nanocrystallised Tablets/Capsules: 145 mg, 160 mg, 200 mg. Ezetimibe Tablets: 10 mg
Fenofibrate Micronised/Nanocrystallised Tablets/Capsules: 145 mg, 160 mg, 200 mg. Ezetimibe Tablets: 10 mg
3. Mechanism of Action & Pharmacodynamics
PPAR-Alpha Agonist Fibrate & Intestinal NPC1L1 Cholesterol Absorption Inhibitor (Schedule H) acting on target receptor/enzyme pathways in Cardiovascular & Antithrombotic Medicines (Ch 03): clinical efficacy is mediated via PPAR-Alpha Agonist Fibrate & Intestinal NPC1L1 Cholesterol Absorption Inhibitor (Schedule H) for Fenofibrate: Severe hypertriglyceridaemia (TG >=500 mg/dL to prevent acute pancreatitis) and diabetic dyslipidaemia/retinopathy. Ezetimibe: Add-on to maximally tolerated statin (or statin-intolerant patients) to achieve LDL-C targets (<55–70 mg/dL in ASCVD).
4. Therapeutic Indications & Evidence-Supported Uses
- Fenofibrate: Severe hypertriglyceridaemia (TG >=500 mg/dL to prevent acute pancreatitis) and diabetic dyslipidaemia/retinopathy
- Ezetimibe: Add-on to maximally tolerated statin (or statin-intolerant patients) to achieve LDL-C targets (<55–70 mg/dL in ASCVD)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Fenofibrate: 145 mg (nanocrystal) or 160–200 mg (micronised) PO OD. Ezetimibe: 10 mg PO OD
Administration & Meal Timing: Take Micronised Fenofibrate (160/200 mg) WITH food (145 mg nanocrystal or Ezetimibe 10 mg may be taken with or without food) | Evening / With Dinner (or anytime for Ezetimibe)
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Fenofibrate: Reduce dose to ~48–67 mg OD if eGFR 30–59 mL/min; CONTRAINDICATED if eGFR <30 mL/min! Ezetimibe: No renal dose adjustment required. Hepatic: Avoid both in active Child–Pugh B/C liver disease
Renal: Fenofibrate: Reduce dose to ~48–67 mg OD if eGFR 30–59 mL/min; CONTRAINDICATED if eGFR <30 mL/min! Ezetimibe: No renal dose adjustment required. Hepatic: Avoid both in active Child–Pugh B/C liver disease
Renal: Fenofibrate: Reduce dose to ~48–67 mg OD if eGFR 30–59 mL/min; CONTRAINDICATED if eGFR <30 mL/min! Ezetimibe: No renal dose adjustment required. Hepatic: Avoid both in active Child–Pugh B/C liver disease
7. Contraindications, Precautions & High-Risk Warnings
- Fenofibrate CONTRAINDICATED in eGFR <30 mL/min, active liver disease, gallbladder disease/cholelithiasis, and severe pancreatitis. Note: Gemfibrozil + Statin is strictly contraindicated; Fenofibrate is preferred if fibrate + statin is essential
Key Clinical Precautions: Renal: Fenofibrate: Reduce dose to ~48–67 mg OD if eGFR 30–59 mL/min; CONTRAINDICATED if eGFR <30 mL/min! Ezetimibe: No renal dose adjustment required. Hepatic: Avoid both in active Child–Pugh B/C liver disease
8. Adverse Effects Profile
- Dyspepsia, mild transaminase elevation, reversible 10–15% rise in serum creatinine (Fenofibrate increases creatinine production without reducing true GFR)
- Myopathy / rhabdomyolysis (especially when Fenofibrate is combined with high-dose Statin in CKD!), cholelithiasis (gallstones), hepatotoxicity
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Fenofibrate potentiates Warfarin (reduce Warfarin by 25–30% and check INR in 3–5 days!); Cyclosporine + Fenofibrate causes severe nephrotoxicity; Cholestyramine binds both drugs (separate by >=4h)
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Report any unexplained muscle pain, tenderness, weakness, or cola-coloured urine immediately; stop alcohol completely if taking Fenofibrate for high triglycerides
- Meal & Clock Timing Instruction: Take Micronised Fenofibrate (160/200 mg) WITH food (145 mg nanocrystal or Ezetimibe 10 mg may be taken with or without food) (Evening / With Dinner (or anytime for Ezetimibe))
- Missed Dose Protocol: Take same day if remembered; skip if next day
- Geriatric Dispensing Pearl: Ezetimibe 10 mg added to moderate-intensity statin is safer than high-intensity statin monotherapy in frail older adults >=75 years
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Fenofibrate Micronised/Nanocrystallised Tablets/Capsules: 145 mg, 160 mg, 200 mg. Ezetimibe Tablets: 10 mg
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 03 [3.43] (p. 42)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [3.4]-CMP1 Perindopril Erbumine IP — Angiotensin II Receptor Blocker (ARB) (Ester Prodrug)
- [3.31]-CMP2 Sumatriptan & Rizatriptan (Acute Migraine 5-HT1B/1D Agonists) — Non-Selective Beta-1 & Beta-2 Adrenoceptor Blocker (Schedule H |
- [3.36]-C3 Valsartan (ARNI Co-Crystal FDC) — Angiotensin Receptor–Neprilysin Inhibitor (Schedule H)
- [3.39]-C4 Isosorbide Dinitrate (ISDN) — Long-Acting Organic Nitrate Venodilators / Nitric Oxide Donors (S
